Stirred-Tank Bioreactor Patents: Leaders, Trends & White Space 2026
- One leader, 21 records, sits well ahead of a fifth-place holder at 8 and a tenth-place holder at 5 — a steep drop-off rather than an even spread.
- Filing peaked in 2022 at 16 records, after climbing from 5 in 2017; the 2026 count is a partial year and understates current activity given typical publication lag.
- C12M bioreactor apparatus classes cover 98.9% of the 93 records in scope, while image processing (G06T, 18.3%) and enzyme/DNA measurement (C12Q, 6.5%) sit far behind — signalling where scale-up patenting has and hasn't reached.
What this landscape covers
Stirred-tank bioreactor scale-up spans the engineering problem of taking a process proven at bench scale — often single-use or glass vessels of a few litres — up to production volumes of thousands of litres while preserving mixing behaviour, oxygen transfer and shear conditions. Patent activity in this dataset centres on tip speed, power density, mixing similarity and oxygen demand as the parameters engineers use to translate a small-scale process into a larger one without re-optimising cell growth from scratch. The search also picks up engineering batch and scale transition framing, which is how claims describe the transfer step itself rather than the vessel alone.
The 93 records in scope run from 2015 through the 2026 cut-off, filed through national offices and the PCT route, and classified predominantly under bioreactor apparatus (C12M) with secondary coverage in microorganism handling (C12N) and mixing equipment (B01F). That composition points to a field still anchored in hardware and process-parameter claims, with measurement and imaging classes present but comparatively thin.
Filing trend and technology composition
Two views of the same 93-record set: how filing has moved year over year, and which IPC subclasses the records sit in.
Filing trend, 2017-2026
Filings rose from 5 in 2017 to a peak of 16 in 2022. The 2026 figure of 0 reflects a partial year and the roughly 18-month lag between filing and publication, not a stop in activity.
IPC composition across 93 records
C12M (bioreactors and enzyme apparatus) appears in 98.9% of records, confirming this is the anchor classification for the search. C12N (microorganisms, 38.7%), B01F (mixing, 25.8%) and B01L (lab apparatus, 24.7%) are the next-heaviest secondary classes; G06T (image processing, 18.3%) and C12Q (enzyme/DNA measurement, 6.5%) mark thinner, more specialised claim territory. Because records carry multiple classes, these shares sum to well over 100% and should be read against the 93-record total, not against each other.
Shares are the percentage of the 93 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Stirred-Tank Bioreactor Scale-Up with Eureka
This page is one run against one query. Ask Eureka your own question about stirred-tank bioreactor scale-up and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this set
EP0291232A1 — Surface immobilisation of plant cells on fibrous supports
A technique for immobilising plant cells on a support surface, depositing cells onto a fibrous support of loosely bound polyester and/or cellulosic fibres so that plant tissue biomass binds strongly while growing in submerged culture. Immobilisation is achieved by simple contact between the support and a cell suspension in culture medium.Filed 1988-11-17 by Canadian Patents and Development Limited — one of the earlier records in this set, illustrating how immobilisation approaches to culture support predate the tip-speed and power-density framing that dominates later filings.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US7384783B2 | Stirred-tank reactor system | 292 |
| 2 | US20050239199A1 | Stirred-tank reactor system | 253 |
| 3 | US20060199260A1 | Microbioreactor for continuous cell culture | 252 |
| 4 | US20050089993A1 | Apparatus and methods for simultaneous operation of miniaturized reactors | 213 |
| 5 | US20060019385A1 | Apparatus and methods for producing and using high-density cells and products therefrom | 94 |
| 6 | US20180010082A1 | Bioreactor With Higher Agitation Rates | 79 |
| 7 | WO2000046354A1 | Apparatus and methods for producing and using high-density cells and products therefrom | 58 |
| 8 | US7507579B2 | Apparatus and methods for simultaneous operation of miniaturized reactors | 53 |
| 9 | US7901934B2 | Probe connector assembly and method of use | 52 |
| 10 | WO2005104706A2 | Stirred-tank reactor system | 52 |
Citation counts accumulate over time, so older filings dominate this table; treat them as markers of influence on later filings, not as a guide to current-day importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for scale-up work
Three read-throughs from the filing trend, the class composition and the citation table.
One assignee dominates a long tail
The leading assignee holds 21 records against a fifth-place holder at 8 and a tenth-place holder at 5. That gap suggests one filer built a broad portfolio early and the rest of the ranked field — 35 companies in total — is far more thinly spread, each holding a handful of records rather than competing head-to-head at volume.
Growth has plateaued, not accelerated
Filings rose from 5 in 2017 to a peak of 16 in 2022. With too few complete years since to compute a reliable growth rate, and the most recent year always undercounted by publication lag, the safest read is that scale-up patenting has settled into a steady rather than rising cadence.
Foundational reactor-system patents still get cited
The most-cited records in this set are stirred-tank reactor system and microbioreactor filings from the mid-2000s, with citation counts well above 200. New entrants should expect any hardware claim touching vessel geometry or miniaturised reactor arrays to sit downstream of this prior art.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to stirred-tank bioreactor scale-up, with the prior art for and against each one.
Who is filing, and where the gate sits
The ranked field runs 35 companies deep, but recent-year momentum has gone quiet across the names with the largest historical portfolios — none of the top co-filing pairs show activity in the latest year.
A single filer with the deepest portfolio
The top-ranked assignee holds 21 records, well clear of the rest of the field, and appears in the strongest co-assignee pairings in this dataset — evidence of a portfolio built through related-entity filing over time rather than one-off applications.
A cluster of established filers
Fifth place sits at 8 records and tenth place at 5, indicating a mid-field of companies with sustained but modest filing programmes rather than a single-patent presence.
Related-entity filing concentrates citations
Ten co-assignee pairs appear in the dataset, with the strongest pairings linking the same small cluster of related corporate entities — a pattern consistent with restructuring or licensing between affiliated filers rather than independent co-invention.
| Assignee | Recent year | YoY |
|---|---|---|
| Baxter International Inc | 0 | — |
| CELLINO BIOTECH INC | 0 | — |
| Baxter Healthcare SA | 0 | — |
| HyClone Laboratories Inc | 0 | — |
| Protein Sciences Corp | 0 | — |
| Finesse Solutions Inc | 0 | — |
| Massachusetts Institute of Technology | 0 | — |
| ZHANG ZHIYU | 0 | — |
Where to take this analysis
The dataset points to a hardware-anchored field with quiet recent momentum among established filers and thin coverage in measurement and imaging classes.
Map the white space claim by claim
Under-claimed branches like mixing-similarity control and power-density sensing sit adjacent to dense C12M apparatus claims — a first filing there needs to be checked against the core reactor-system prior art before drafting.
Explore white space in EurekaTrack the quiet leaders
Recent-year momentum has dropped to zero across the largest historical filers; watch for renewed activity or new entrants as publication catches up with 2025-2026 filings.
Set up assignee monitoring in EurekaCommon questions on stirred-tank bioreactor scale-up patents
One assignee leads the ranked field with 21 records, well ahead of the fifth-place holder at 8 and tenth place at 5. That gap indicates a single company built a broad early portfolio, while the remaining 35 ranked companies each hold smaller, more specialised sets of filings. The leader also appears in the strongest co-assignee pairings in the dataset, suggesting the portfolio grew partly through related-entity filing rather than solely independent invention.
Filings rose from 5 records in 2017 to a peak of 16 in 2022, but there are not enough complete years since then to compute a reliable growth rate. The 2026 count looks low mainly because publication typically lags filing by around 18 months, so recent activity is undercounted rather than absent. The overall pattern reads as a plateau following the 2022 peak rather than continued acceleration.
Bioreactor and enzyme apparatus classification (C12M) covers 98.9% of the 93 records in scope, confirming that hardware and vessel-level claims anchor this field. Microorganism and genetic-engineering classification (C12N) appears in 38.7% of records, and mixing equipment (B01F) in 25.8%, both as common secondary classifications alongside the core apparatus claims. Image processing (G06T, 18.3%) and enzyme/DNA measurement (C12Q, 6.5%) are present but comparatively thin, marking areas with less claim density.
The highest-citation records in this dataset are stirred-tank reactor system and microbioreactor filings, with the top record cited 292 times and others in the same cluster cited in the low-to-mid 200s. These are mid-2000s filings, so their high citation counts reflect years of accumulated influence on later work rather than current-day novelty. Anyone filing new hardware claims around vessel geometry or miniaturised reactor arrays should expect to sit downstream of this prior art.
The class composition shows measurement and imaging-related classes — enzyme/DNA-based monitoring, image-based oxygen-transfer tracking, and mixing-similarity control algorithms — appearing far less often than the core apparatus and mixing classes. Combined with quiet recent-year momentum among the largest historical filers, this suggests openings for narrowly drafted claims in sensor integration, automated calibration and control-software approaches layered on top of conventional stirred-tank hardware. A first claim in these areas should be checked against the dense core apparatus prior art before drafting.
Research Stirred-Tank Bioreactor Scale-Up in depth with Eureka
Go past this page: query the whole stirred-tank bioreactor scale-up corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.